Skip to main content
. 2015 Dec 30;2015:595363. doi: 10.1155/2015/595363

Figure 1.

Figure 1

Concept of mutanome engineered RNA immunotherapy (MERIT). Next generation sequencing of nucleic acid from a tumor biopsy and healthy tissue is used to identify expressed, nonsynonymous, somatic mutations. Vaccine targets are selected based on several parameters such as expression, their MHC binding prediction, and restriction as well as a false discovery rate (FDR) [16]. Mutations encoded on pentatope RNAs are produced under GMP conditions and used for therapeutic vaccination.